The Valley Desk

NCT04676477 · Interventional trial

HER3-DXd (Patritumab Deruxtecan; U3-1402) in Combination With Osimertinib in Subjects With Locally Advanced or Metastatic EGFR-mutated Non-Small Cell Lung Cancer

Overall registry status Active not recruiting

Phase 1

Conditions Non-Small Cell Lung Cancer (NSCLC)

Delaware Valley sites

First posted

Registry updated

Added to the directory

View this study on ClinicalTrials.gov